The Pharma Legal Handbook: Japan

Japan is the world's third largest pharmaceutical market by value and one of its most demanding regulatory environments. The Pharmaceuticals and Medical Devices Agency (PMDA) manages product review and registration, while the Ministry of Health, Labour and Welfare (MHLW) makes final approval decisions and oversees the National Health Insurance (NHI) pricing system.

Japan's NHI pricing system is one of the most consequential pricing mechanisms in the global pharmaceutical industry. The listing price set by MHLW at launch, the biennial price revisions, and the rules around premium pricing for innovative medicines all have significant commercial implications that market access teams need to understand in detail.

The Pharma Legal Handbook: Japan provides comprehensive guidance on pharmaceutical regulation in Japan, covering PMDA review and MHLW approval processes, NHI pricing and listing, clinical trial requirements, pharmacovigilance obligations, manufacturing and GMP requirements, marketing rules, and intellectual property protection.